385 related articles for article (PubMed ID: 11678828)
1. Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion.
Muller AF; Janssen JA; Lamberts SW; Bidlingmaier M; Strasburger CJ; Hofland L; van der Lely AJ
Clin Endocrinol (Oxf); 2001 Oct; 55(4):461-7. PubMed ID: 11678828
[TBL] [Abstract][Full Text] [Related]
2. Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance.
Muller AF; Janssen JA; Hofland LJ; Lamberts SW; Bidlingmaier M; Strasburger CJ; van der Lely AJ
J Clin Endocrinol Metab; 2001 Feb; 86(2):590-3. PubMed ID: 11158013
[TBL] [Abstract][Full Text] [Related]
3. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.
Veldhuis JD; Bidlingmaier M; Anderson SM; Wu Z; Strasburger CJ
J Clin Endocrinol Metab; 2001 Jul; 86(7):3304-10. PubMed ID: 11443205
[TBL] [Abstract][Full Text] [Related]
4. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Awouters M; Verbruggen W; Schetz M; Verwaest C; Lauwers P; Bouillon R; Bowers CY
J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.
Bowers CY; Granda-Ayala R
Endocrine; 2001 Feb; 14(1):79-86. PubMed ID: 11322505
[TBL] [Abstract][Full Text] [Related]
6. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
Van den Berghe G; de Zegher F; Bowers CY; Wouters P; Muller P; Soetens F; Vlasselaers D; Schetz M; Verwaest C; Lauwers P; Bouillon R
Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573
[TBL] [Abstract][Full Text] [Related]
7. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.
Bowers CY; Granda R; Mohan S; Kuipers J; Baylink D; Veldhuis JD
J Clin Endocrinol Metab; 2004 May; 89(5):2290-300. PubMed ID: 15126555
[TBL] [Abstract][Full Text] [Related]
8. Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone.
Van den Berghe G; Wouters P; Carlsson L; Baxter RC; Bouillon R; Bowers CY
J Clin Endocrinol Metab; 1998 Sep; 83(9):3062-70. PubMed ID: 9745404
[TBL] [Abstract][Full Text] [Related]
9. Acute dexamethasone administration enhances GH responsiveness to GH releasing peptide-6 (GHRP-6) in man.
Pinto AC; Finamor FE; Lengyel AM
Clin Endocrinol (Oxf); 1999 Oct; 51(4):409-14. PubMed ID: 10583306
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone (GH) response to GH-releasing peptide-6 in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion.
Catalina PF; Mallo F; Andrade MA; García-Mayor RV; Diéguez C
J Clin Endocrinol Metab; 1998 Oct; 83(10):3663-7. PubMed ID: 9768681
[TBL] [Abstract][Full Text] [Related]
11. Different effects of growth hormone releasing peptide (GHRP-6) and GH-releasing hormone on GH release in endogenous and exogenous hypercortisolism.
Borges MH; DiNinno FB; Lengyel AM
Clin Endocrinol (Oxf); 1997 Jun; 46(6):713-8. PubMed ID: 9274702
[TBL] [Abstract][Full Text] [Related]
12. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men.
Veldhuis JD; Bowers CY
Am J Physiol Endocrinol Metab; 2009 May; 296(5):E1085-92. PubMed ID: 19240251
[TBL] [Abstract][Full Text] [Related]
13. E2 supplementation selectively relieves GH's autonegative feedback on GH-releasing peptide-2-stimulated GH secretion.
Anderson SM; Wideman L; Patrie JT; Weltman A; Bowers CY; Veldhuis JD
J Clin Endocrinol Metab; 2001 Dec; 86(12):5904-11. PubMed ID: 11739462
[TBL] [Abstract][Full Text] [Related]
14. Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency.
Muller AF; Leebeek FW; Janssen JA; Lamberts SW; Hofland L; van der Lely AJ
J Clin Endocrinol Metab; 2001 Nov; 86(11):5165-71. PubMed ID: 11701672
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood.
Micic D; Popovic V; Kendereski A; Macut D; Casanueva FF; Dieguez C
Clin Endocrinol (Oxf); 1995 Feb; 42(2):191-4. PubMed ID: 7734029
[TBL] [Abstract][Full Text] [Related]
16. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus.
Huhn WC; Hartman ML; Pezzoli SS; Thorner MO
J Clin Endocrinol Metab; 1993 May; 76(5):1202-8. PubMed ID: 8496311
[TBL] [Abstract][Full Text] [Related]
17. Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues.
Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Gouwy S; Stockman W; Weekers F; Schetz M; Lauwers P; Bouillon R; Bowers CY
Clin Endocrinol (Oxf); 1997 Nov; 47(5):599-612. PubMed ID: 9425400
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone-releasing peptides: clinical and basic aspects.
Argente J; García-Segura LM; Pozo J; Chowen JA
Horm Res; 1996; 46(4-5):155-9. PubMed ID: 8950613
[TBL] [Abstract][Full Text] [Related]
19. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults.
Popovic V; Leal A; Micic D; Koppeschaar HP; Torres E; Paramo C; Obradovic S; Dieguez C; Casanueva FF
Lancet; 2000 Sep; 356(9236):1137-42. PubMed ID: 11030292
[TBL] [Abstract][Full Text] [Related]
20. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection.
Pombo M; Barreiro J; Peñalva A; Peino R; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1995 Nov; 80(11):3180-4. PubMed ID: 7593423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
